Immune thrombocytopenic purpura
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, lower IL-4 level (<3.5 pg/ml), higher WBC (>6.37*10<sup>9</sup>/L), and higher platelet count (>12 * 10<sup>9</sup>/L) at diagnosis were favorable predictive factors for IVIG response in the newly diagnosed ITP.
|
31129375 |
2019 |
Immune thrombocytopenic purpura
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The level of IFN-γ in ITP group remained higher after anti-PD-1 blockage, but the levels of IL-4, TGF-β, and IL-17 were not significantly influenced.sPD-1 may cause the dysfunction of PD-1/PD-L1 signaling pathway, and its level is related to the severity of ITP patients.
|
31651870 |
2019 |
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
A passive platelet antibody model was used to generate ITP in IL-4 receptor knock-out (IL-4R<sup>-/-</sup> ), IL-11 receptor knock-out (IL-11Rα<sup>-/-</sup> ) and GM-CSF knock-out (Csf2<sup>-/-</sup> ) mice.
|
29704458 |
2018 |
Immune thrombocytopenic purpura
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Integrated network pharmacology and metabolomics analysis of the therapeutic effects of ZDF on ITP may be as follows: ZDF counteracts ITP symptoms mainly by inhibiting Ras/MAPKs (Ras/Mitogen-activated protein kinases) pathway, and the expression of upstream protein (Ras) and downstream protein (p-ERK, p-JNK, p-p38) were inhibited, which affects the content of effect index associated with proliferation (Thrombopoietin, TPO; Granulocyte-macrophage colony stimulating factor, GM-CSF), inflammation (Tumor necrosis factor-α, TNF-α; Interleukin-6, IL-6), immune (Interleukin-2, IL-2; Interferon-gamma, IFN-γ; Interleukin-4, IL-4), so that the body's arginine, Δ<sup>12</sup>-prostaglandin j2 (Δ<sup>12</sup>-PGJ2), 9-<i>cis</i>-Retinoic Acid, sphingosine-1-phosphate (S1P), oleic acid amide and other 12 endogenous metabolites significantly changes.
|
29971001 |
2018 |
Immune thrombocytopenic purpura
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The pre- and post-treatment plasma and mRNA levels of IFN-γ and IL-2 were significantly higher, while the pre- and post-treatment IL-4 levels as well as the pre-treatment TGF-β1 levels were remarkably lower in ITP patients compared with HCs.
|
28142109 |
2017 |
Immune thrombocytopenic purpura
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The messenger RNA expression levels of the indicated genes, including HLA-DRB5, IGHV3-66, IFI27, FAM212A, PLD5, tumor necrosis factor (TNF)-α, interferon-γ, interleukin (IL)-1β, and IL-4, were significantly increased in patients with ITP compared with healthy humans, while MMP8, SLC1A3, CRISP3, THBS1, FMN1, and IL-10 were decreased.
|
27554456 |
2017 |
Immune thrombocytopenic purpura
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
IL4 and IL10 gene polymorphisms may contribute to susceptibility for ITP in children.
|
25051072 |
2014 |
Immune thrombocytopenic purpura
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We also counted platelets and evaluated plasma IFN-γ, IL-18 and IL-4 levels in patients with active ITP (n=26), patients with ITP in remission (n=23) and in healthy subjects (n=34) by enzyme linked immunosorbent assay (ELISA).
|
24231118 |
2014 |
Immune thrombocytopenic purpura
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This was also reflected in plasma with increased levels of interleukin (IL)-16 and TNF-related weak inducer of apoptosis and lower levels of IL-4 in newly diagnosed compared with chronic ITP.
|
23869085 |
2013 |
Immune thrombocytopenic purpura
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The levels of plasma IL-4 in ITP patients with active disease and in remission were significantly higher than that of controls (p = 0.0093, p = 0.0053, respectively).
|
22111667 |
2012 |
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, in an autoimmune disorder-primary immune thrombocytopenia, TIMP-3 showed a statistically positive correlation with IL-4 and platelet count, but a negative correlation with IFN-γ in patient blood samples.
|
22415751 |
2012 |
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
Most importantly, the Th1/Th2 (IFN-gamma/IL-4) was remarkably higher in ITP patients, showing that the ITP patients were mainly in the Th1 polarization response.
|
20100010 |
2010 |
Immune thrombocytopenic purpura
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To evaluate the balance of interleukin IL18 and its endogenous antagonist IL18 binding protein (IL18BP) in patients with idiopathic thrombocytopenic purpura (ITP), plasma IL18, IL18BP, interferon gamma (IFNG) and IL4 levels, as well as platelet counts were measured in patients with active ITP (n = 23), ITP in remission (n = 21) and in healthy subjects (n = 24) by enzyme linked immunosorbent assay (ELISA).
|
19077159 |
2009 |
Immune thrombocytopenic purpura
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To evaluate the effects of high-dose dexamethasone (HD-DXM) on the balance of interleukin-18 (IL-18) and its endogenous antagonist IL-18 binding protein (IL-18BP) in ITP patients, IL-18, IL-18BP as well as IFN-gamma, IL-4 plasma levels and platelet counts were determined in 17 ITP patients receiving DXM 40 mg/day for four consecutive days and in 24 healthy subjects.
|
19797730 |
2009 |
Immune thrombocytopenic purpura
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There was no association between IFN-gamma +874A/T and IL-4 intron3 VNTR polymorphism and ITP risk when all patients, as a group, were analyzed.
|
17655693 |
2007 |
Immune thrombocytopenic purpura
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expressions of bcl-2 mRNA in ITP children increased significantly, but the expressions of bax mRNA decreased, the ratios of bcl-2/bax mRNA were improved obviously and there were positive correlation between the ratios of Th1/Th2 (IFN-gamma(+)T/IL-4(+)T) and the ratios of bcl-2/bax mRNA.
|
17474894 |
2007 |
Immune thrombocytopenic purpura
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This finding suggests that the IL-4 intron 3 and IL-10 (-627) polymorphisms contribute to the susceptibility of developing childhood chronic ITP.
|
15755291 |
2005 |